Drugs / SHEN211 Tablets
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06288893 Comparator | Apr → Aug 2024 | COVID-19 | JKT Biopharma Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHEN211 Tablets | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06288893 ↗ |
| Route | Oral | “110 mg (1 tablet) SHEN211 tablets QD orally on Days 2-5.” NCT06288893 ↗ |